NATIONAL INSTITUTES OF HEALTH

National Cancer Institute Bethesda, Maryland

AGENDA

168th Meeting of the

NATIONAL CANCER ADVISORY BOARD

3-4 September 2024

Tuesday, 3 September – Open

Gaithersburg Marriott, Washingtonian Center - See Subcommittee Meetings Listing Subcommittee Meetings

6:00 p.m. – 7:00 p.m.

Ad Hoc Subcommittee on Experimental Therapeutics

7:15 p.m. – 8:15 p.m.

Ad Hoc Subcommittee on Population Science, Epidemiology and Disparities

Wednesday, 4 September – Open

National Cancer Institute, Shady Grove Campus, Terrace Level, Conference Room TE 406 NCAB Meeting

9:00 a.m. - 9:05 a.m.

Call to Order and Opening Remarks

Dr. Carpten

- Consideration of Meeting Summary:
 - 11-13 June 2024 Joint BSA/NCAB Meeting
- Conflict of Interest
- Future Meeting Dates:

NCAB Confirmed:

December 2-4, 2024 - Joint	Monday, Tuesday, Wednesday
February 13, 2025 - Virtual	Thursday
June 10-12, 2025 - Joint	Tuesday, Wednesday, Thursday
September 2-4, 2025	Tuesday, Wednesday, Thursday
December 1-3, 2025 - Joint	Monday, Tuesday, Wednesday
February 12, 2026 - Virtual	Thursday
June 10-11, 2026 - Joint	Wednesday, Thursday
September 2-3, 2026	Wednesday, Thursday
December 1-2, 2026 - Joint	Tuesday, Wednesday

9:05 a.m. – 9:45 a.m.

NCI Director's Report Dr. Rathmell

9:45 a.m. – 10:15 a.m.

Budget Update Dr. Lowy

Mr. Ricks

<u>10:15 a.m. – 10:35 a.m.</u>

Legislative Report Ms. Holohan

10:35 a.m. – 10:45 a.m.

Recognition of Retiring Members Dr. Rathmell

10:45 <u>a.m. – 11:20 a.m.</u>

NCI's Support of Early Career Cancer Investigators Dr. Bogler

Dr. Davani Dr. Calzola

<u>11:20 a.m. – 11:35 a.m.</u>

Coffee Break

11:35 a.m. – 12:10 p.m.

Childhood Cancer Data Initiative (CCDI) Dr. Widemann

> Dr. Leary Dr. Thomas

12:10 p.m. – 1:10 p.m.

Lunch

1:10 p.m. – 1:45 p.m.

Overview: NCI and Artificial Intelligence (AI) Dr. Kibbe

> Dr. Klemm Dr. Turkbey

Dr. Winkfield

1:45 p.m. – 2:30 p.m.

Update: NCI Community Oncology Research Program (NCORP) Dr. Castle

and the National Clinical Trials Network (NCTN) Dr. Doroshow

2:30 p.m. – 3:15 p.m.

3:15 p.m. – 3:30 p.m.

Ongoing and New Business Dr. Carpten

• Subcommittee Reports:

- Ad Hoc Subcommittee on Experimental Therapeutics Dr. Boxer

- Ad Hoc Subcommittee on Population Science, Epidemiology and Disparities

• Future Agenda Items

• Informational Items

Coffee Break and Adjournment of Open Session

Wednesday, 4 September – Closed

National Cancer Institute, Shady Grove Campus, Terrace Level, Conference Room TE 406 NCAB Closed Session

3:30 p.m. – 4:30 p.m.

NCAB Closed Session

This portion of the meeting is being closed to the public in accordance with the Provisions set forth in Sections 552b(c) (4), 552b(c) (6). Title 5 U.S. Code and 10(d) of The Federal Advisory Committee Act, as amended (5 U.S.C. appendix 2).

- Grants Review
- Discussion of Personnel and Proprietary Issues

4:30 p.m.

Adjournment of NCAB Closed Session

<u>Subcommittee Meetings – Open</u>

Gaithersburg Marriott Washingtonian Center 9751 Washington Blvd. Gaithersburg, MD 20878 Salons A-B

Tuesday, 3 September 2024

Ad Hoc Subcommittee on Experimental Therapeutics 6:00 p.m. - 7:00 p.m.

Ad Hoc Subcommittee on Population Science, Epidemiology, and Disparities $7:15~\rm{p.m.} - 8:15~\rm{p.m.}$

Speakers

Oliver Bogler, Ph.D.

Director Center for Cancer Training National Cancer Institute National Institutes of Health Bethesda, MD

Jessica M. Calzola, Ph.D.

Branch Director Innovative Programs Branch National Cancer Institute National Institutes of Health Bethesda, MD

Philip Castle, Ph.D.

Director
Division of Cancer Prevention
National Cancer Institute
National Institutes of Health
Bethesda, MD

Behrous Davani, Ph.D.

Branch Director
Diversity Training and Biomedical Workforce Development Branch
National Cancer Institute
National Institutes of Health
Bethesda, MD

James H. Doroshow, M.D.

Director
Division of Cancer Treatment Diagnosis
National Cancer Institute
National Institutes of Health
Bethesda, MD

M.K. Holohan, J.D.

Director
Office of Government and Congressional Relations
National Cancer Institute
National Institutes of Health
Bethesda, MD

Warren A. Kibbe, Ph.D.

Deputy Director
Data Science and Strategy
National Cancer Institute
National Institutes of Health
Bethesda, MD

Juli Klemm, Ph.D.

Program Director
Center for Strategic Scientific Initiatives (CSSI)
National Cancer Institute
National Institutes of Health
Bethesda, MD

Sarah E. S. Leary, M.D., M.S.

Attending Physician and Medical Director
Pediatric Brain Tumor Program
Professor
Department of Pediatrics
University of Washington School of Medicine
Seattle, WA

Douglas Lowy, M.D.

Principal Deputy Director National Cancer Institute National Institutes of Health Bethesda, MD

Kimryn Rathmell, M.D., Ph.D.

Director National Cancer Institute National Institutes of Health Bethesda, MD

Mr. Weston Ricks, M.B.A.

Director
Office of Budget and Finance
National Cancer Institute
National Institutes of Health
Bethesda, MD

Diana L. Thomas, M.D., Ph.D.

Operations Director Anatomic Pathology Biopathology Center Nationwide Children's Hospital Columbus, OH

Ismail Baris Turkbey, M.D.

Senior Clinician
Molecular Imaging Branch
Head
Artificial Intelligence Resource
National Cancer Institute
National Institutes of Health
Bethesda, MD

Brigitte C. Widemann, M.D.

Chief Pediatric Oncology Branch Head

Pharmacology and Experimental Therapeutics Section Special Advisor to the NCI Director for Childhood Cancer National Cancer Institute National Institutes of Health Bethesda, MD